Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Cardiology > Clinical Electrophysiology IV > Flashcards

Clinical Electrophysiology IV Flashcards

1
Q

Evaulation of Cardiac Arrhythmias

  • Symptoms due to an abnormal rhythm
  • Goal of arrhythmia evaluations
A
  • Symptoms due to an abnormal rhythm
    • Palpitations: unusual awareness of the heart beta
    • Tachycardia: rapid heart beat
    • Syncope: loss of consciousness
    • Presyncope: dizziness, lightheadedness
    • Chest pain
  • Goal of arrhythmia evaluations
    • Correlate symptoms w/ rhythm abnormality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

12 Lead ECG

  • General
  • Assessment
  • Pros
  • Cons
A
  • General
    • Noninvasive tool
    • First step
  • Assessment
    • Heart rate
    • Conduction disease or abnormalities like WPW syndrome
    • Evidence of a prior MI
    • Evidence of various atrial or ventricular arrhythmias
  • Pros
    • Painless
    • Widely available
    • Inexpensive
  • Cons
    • Limited to a single 10 second recording of heart rhythm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Ambulatory or Holter Monitoring

  • General
  • Assessment
  • Pros
  • Cons
A
  • General
    • Noninvasive tool
    • Records heart rhythms for 24 hours
  • Assessment
    • Frequency of ectopic beats
    • Average heart rate
    • Episodies of tachycardia & bradycardia
  • Pros
    • Can see if the rhythm distrubances or symptoms occur at least once during the 24-hour period
  • Cons
    • Possible to miss an arrhythmic episode if an event doesn’t occur during the 24-hour period
    • may fail to correlate symptoms w/ an abnormal rhythm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Patient Activated Event (“Loop,” “King of Hearts”) Recorders

  • General
  • Pros
  • Cons
A
  • General
    • Noninvasive tool
    • Patients activate the recorder when they feel symptoms
    • Rhythm recorded on the device is transmitted via telephone to the central station for interpretation
  • Pros
    • Assesses symptoms that occur less than daily buare are likely to occur ina reasonable period of time
  • Cons
    • Patients may not be able to activate the recorder at the time of the symptoms due to physical frailty or syncope
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Implantable Loop Recorder

A
  • Noninvasive tool
  • Automatically records when it senses pauses, slow or fast HRs, or when the patient notices symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cardionet

  • General
  • Pros
A
  • General
    • Noninvasive tool
    • External loop recorder
    • Wearable monitor w/ a base unit that continuously transmits the rhythm to a central monitoring center for interprtetation & monitoring
  • Pros
    • Good for patients that may not have time to activate a monitor prior to syncope or who don’t “feel” the arrhythmia (ex. atrial fibrillation)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Signal Average ECG (SAECG)

  • General
  • Assessment
  • Cons
A
  • General
    • Noninvasive tool
    • Based on the assumption that areas of arrythmogenic ventricular muscle exhibit slow conduction that will be manifested as small potentials near the end of the QRS complex
    • Late potentials aren’t seen on the avg ECG b/c of filtering that limits noise
    • If hundreds of QRS complexes are averaged, the “random noise” is cancelled out & these “late potentials” can be seen
  • Assessment
    • Assesses patient’s risk of sudden cardiac death
    • Predicts future mortality after a MI
    • Not correlated w/ a symptom
  • Cons
    • Specificity is decreased if a patient has a baseline conduction abnormality (ex. BBB) or the noise level of the SAECG > 0.5
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Heart Rate Variability (HRV)

  • General
  • Methods
  • Assessment
  • Pros
A
  • General
    • Noninvasive tool
    • Looks at cyclic changes in HR by analyzing the time b/n consecutive heart beats
  • Methods
    • Standard statistical methods
      • Time domain analysis
    • Transformation into the frequency domain
      • Uses the Fast Fourier Transform
      • Frequency domain analysis
  • Assessment
    • Arrhythmic risk
    • Decreases in parasympathetic (primarily vagal) activity are associated w/ increased mortality in post-MI patients
  • Pros
    • Decreased HR variability better predicts arrhythmic events than the SAECG, stress test, or EF measurements
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

T Wave Alternans

  • General
  • Assessment
A
  • General
    • Noninvasive tool
    • Look sfor microvolt changes in the size of the t wave
    • Alternating patterns of big & small amplitude t waves correlate w/ an increased risk for ventricular arrhythmias
  • Assessment
    • Patients who aren’t at risk for cardiac arrhythmias
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Electrophysiology (EP) Study

  • General
  • Method
  • Programmed electrical stimulation
  • Specialized studies
A
  • General
    • Invasive tool
    • Gold standard for evaluating cardiac arrhythmias
  • Method
    • Insert catheters to record intracardiac signals from critical regions of the cardiac conducting system
    • Catheters are normally placed near the SA node, AV node, Bundle of His, & RV apex
  • Programmed electrical stimulation
    • Catethers introduce pacing sitmuli & record to study the conducting system or induce arrhythmias (typically those w/ a reentrant mechanism)
  • Specialized studies
    • Catheters are placed into hte LV, LA, or coronary sinus
    • Recordings of conduction times & location where conduction fails or is blocked allows assessment of SA & AV nodal function
    • Determiens the need for a permanent pacemaker
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Computer Based Mapping Systems

A
  • Invasive tools
  • Introduce extra stimuli to reproduce reentrant arrhythmias
    • Ex. VT associated w/ CAD, many types of SVT
  • Map the location of the focus or circuit responsible for the abnormal rhythm
  • Use GPS-like technology to construct 3D images of cardiac activation
  • Speeds ablation
  • Makes it possible to perform new procedures
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Vaugn-Williams Antiarrhythmic Drugs: Classification & Representative Drugs

  • Class I
    • IA
    • IB
    • IC
  • Class II
  • Class III
  • Class IV
A
  • Class I: sodium channel blockers
    • IA
      • Procainamide
      • Quinadine
      • DIsopyramide
    • IB
      • Lidocaine
      • Mexilitine
      • Tocainide
    • IC
      • Flecainide
      • Encainide
      • Propafenone
  • Class II: beta blockers
    • Propranolol
    • Atenolol
    • Metoprolol
    • Timolol
    • Naldolol
    • Esmolol
  • Class III: potassium channel blockers
    • Amiodarone
    • Bretylium
    • NAPA
    • Sotalol
    • Dofetilide
  • Class IV: calcium channel blockers
    • Verapamil
    • Diltiazem
    • Nifedipine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Vaugn-Williams Antiarrhythmic Drugs: Effects

  • Class I
    • IA
    • IB
    • IC
  • Class II
  • Class III
  • Class IV
A
  • Class I: sodium channel blockers
    • IA
      • Increase AP duration & Effective Refractory Period (ERP)
      • Increase QRS & QT duration
      • Decrease slope phase 0
    • IB
      • Neutral effect on ERP
      • Decrease AP & QT duration
      • Decrease slope phase 0
    • IC
      • Neutral effect on ERP & AP duration
      • Decrease slope phase 0 & 4
  • Class II: beta blockers
    • Increase AV nodal refractoriness
    • Decrease AV conduction
    • Decrease chronotropy
  • Class III: potassium channel blockers
    • Increase AP duration & ERP
    • Increase PR interval
    • Increase QRS duration
    • Increase QT duration
  • Class IV: calcium channel blockers
    • Increase ERP of AV node
    • Block slow Ca2+ current
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Vaugn-Williams Antiarrhythmic Drugs: Side Effects

  • Class I
  • Class II
  • Class III
    • Amiodarone
    • Sotolol
    • Dofetilide
  • Class IV
A
  • Class I: sodium channel blockers
    • *GI distress
    • CNS symptoms
    • Allergic reactions
    • *Lupus
    • Thrombocytopenia
    • Pro-arrhythmia
    • *Syncope (Quinidine)
  • Class II: beta blockers
    • Hypotension
    • Bradycardia
    • Worsening CHF
    • Worsening asthma or COPD
  • Class III: potassium channel blockers
    • Amiodarone
      • *Pulmonary toxicity
      • Bradycardia
      • GI symptoms
      • *Thyroid & liver abnormalities (hypothyroidism)
    • Sotolol
      • Class II effects + pro-arrhythmia
      • Contraindicated in patients w/ renal dysfunction
    • Dofetilide
      • Torsade de pointes
      • Contraindicated in patients w/ renal dysfunction
  • Class IV: calcium channel blockers
    • Hypotension
      Bradycardia
    • Worsening AV block
    • Liver function abnormalities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Medical Therapy for Supraventricular Arrhythmias

  • Treatment for supraventricular arrhythmias
  • Treatment for supraventricular arrhythmias where the AV node is part of the arrhythmia circuit
  • Treatment not effective in atrial rhythm abnormalities
A
  • Treatment for supraventricular arrhythmias
    • Class IA, IC, & III antiarrhythmic drugs
  • Treatment for supraventricular arrhythmias where the AV node is part of the arrhythmia circuit
    • Class IA, IC, & III antiarrhythmic drugs
    • Class II & IV antiarrhythmic drugs for their AV nodal blocking properties
  • Treatment not effective in atrial rhythm abnormalities
    • Class IB antiarrhythmic drugs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Clinical Risk Factors for Stroke

  • High risk
  • Moderate risk
  • Low risk (“lone atrial fibrillation”)
A
  • High risk
    • Rheumatic valvular disease
  • Moderate risk
    • CHF within last 3 months
    • History of HTN
    • History of arterial thromboemboli
    • Global LV dysfunction
    • LA size > 4.7 cm
    • Left sided valvular abnormalities
  • Low risk (“lone atrial fibrillation”)
    • Absnece of all other risk factors
    • Under 60yo
17
Q

Atrial Fibrillation & Flutter

  • Atrial fibrillation
  • Anti-thrombotic therapy
  • CHADS2 Score
  • Warfarin vs. aspirin
A
  • Atrial fibrillation
    • Most common abnormal rhythm found in adults
    • Treatment: treat abnormal rhythm + prevent embolic complications
  • Anti-thrombotic therapy
    • Essential for treating both atrial fibrillation & flutter
    • Afib patients: at high risk for strokes if not receiving anticoagulation
  • CHADS2 Score
    • Assigns points for each risk factor
      • 2 points: prior stroke or TIA
      • 1 point: >75yo, HTN, diabetes, heart failure
    • Guideline recommendations
      • 0 points: no therapy
      • 1 point: aspirin or warfarin
      • _>_2: warfarin
  • Warfarin vs. aspirin
    • Warfarin: higher stroke risk reduction, higher risk of bleeding
    • Aspirin: lower stroke risk reduction, lower risk of bleeding
    • Except for patients w/ lone atrial fibrillation, anticoagulation w/ warfarin should be used unless the patient is contraindicated (ex. elderly w/ increased risk of bleeding)
18
Q

Atrial Fibrillation & Flutter: Timing & Duration of Anticoagulation

  • AFib < 48 hours
  • AFib > 48 hours or unknown
  • AFib > 48 hours or unknown but can’t wait 3 weeks
  • All cases
A
  • AFib < 48 hours
    • Low stroke risk, so attempt to restore sinus rhythm
  • AFib > 48 hours or unknown
    • Anticoagulate for 3 weeks before attempting to restore sinus rhythm
  • AFib > 48 hours or unknown but can’t wait 3 weeks
    • Initiate anticoagulation
    • Inspect the LA for thrombus by transesophageal echo
    • If LA is thrombus-free, risk of thromboemboli from cardioversion is ~= to the risk of thromboemboli following 3 weeks of anticoagulation, so attempt to restore sinus rhythm
  • All cases
    • Maintain an INR for _>_3 weeks after sinus rhythm is restored, even w/ a negative transesophageal echo
19
Q

Atrial Fibrillation & Flutter: Timing & Duration of Anticoagulation

  • AFFIRM trial
  • Current conditions for which anticoagulation & rate control are needed
  • Treatment for patient w/ disabling symptoms
  • Treatment for permanent AFib
  • Treatment for a patient w/ appropriate antithrombotic therapy that needs to restore sinus rhythm
  • Treatment of AFib in patients w/ WPW syndrome
A
  • AFFIRM trial
    • When managing AFib, a rhythm control strategy (restoring sinus rhythm) has no survival advantage over a rate control strategy (keeping the ventricular rate from beating too fast)
  • Current conditions for which anticoagulation & rate control are needed
    • Recurrent paroxysmal AFib
    • Recurrent persistent AFib
  • Treatment for patient w/ disabling symptoms
    • Consider antiarrhythmic drugs (rhythm control) & potential electrical cardioversion
  • Treatment for permanent AFib
    • Anticoagulation & rate control as needed
    • Ventricular rate control w/ concomitant antithrombotic therapy increases block in the AV node so the resulting ventricular rate/response is slowed
  • Treatment for a patient w/ appropriate antithrombotic therapy that needs to restore sinus rhythm
    • Cardioversion: electrical, synchronized transthoracic direct current counter-shock that terminates activity in the chaotic atrial foci to allow SA activity to emerge
    • Antiarrhythmic drugs: used for chemical cardioversion
      • Not as effective, but may be useful in patients when anesthesia (needed for electrical cardioversion) may pose additional risks
    • Risk fo periconversion stroke is the same for electrical & chemical cardioversion
  • Treatment of AFib in patients w/ WPW syndrome
    • AV nodal blocking agent (ex. digoxin) –> allows atrial conduction through the accessory pathway –> doesn’t slow conduction –> sudden cardiac death –> don’t use these
    • Procainamide / amiodarone –> slow both AV nodal & accessory pathway conduction –> avoid rapid ventricular response –> use these
20
Q

Treatment Comparisons for HR Control in Atrial Fibrillation

  • Digoxin
    • Advantages
    • Disadvantages
  • Beta & calcium channel blockers
    • Advantages
    • Disadvantages
  • Amiodarone
    • Advantages
    • Disadvantages
  • AV node ablation
    • Advantages
    • Disadvantages
A
  • Digoxin
    • Advantages
      • Inexpensive
      • Widely available
    • Disadvantages
      • Poorly controls rate during activity
      • Digitalis toxicity
  • Beta & calcium channel blockers
    • Advantages
      • Controls rate well during activity
      • Relatively inexpensive
      • Widely available
    • Disadvantages
      • Effective rate controlling doses can have intolerable side effects
  • Amiodarone
    • Advantages
      • May help restore sinus rhythm
      • Widely available
    • Disadvantages
      • Pulmonary & thyroid side effects
      • Interactions w/ other drugs (warfarin)
      • Bradycardia & long half-life
  • AV node ablation
    • Advantages
      • Complete control of ventricular rate
    • Disadvantages
      • Requries life long permanent pacemaker
21
Q

ICD vs. Drug Therapy for Ventricular Arrhythmias

A
  • Implantable cardioverter defibrillator (ICD) has largely eliminated drug therapy
    • Esp in patients w/ a prior MI & depresed EF
  • Sometimes, drugs are used in conjunction w/ ICD therapy to suppress ventriculra ectopy & reduce shocks from the defibrillator
22
Q

Catheter Ablation Therapy for Arrhythmias

  • Procedure
  • Treats…
A
  • Procedure
    • Apply radiofrequency energy to a critical protion of the tachycardia circuit that was identified during an EP study
    • Safe, low morbidity, no mortality, & >95% cure rate
  • Treats…
    • Supraventricular tachycardias
    • AV node reentry tachycardia
    • SVT associated w/ WPW syndrome
    • AFib
    • Ventricular tachycardia
23
Q

Device Related Therapy

  • General
  • Categories
A
  • General
    • Implanted devices that help maintain the appropriate heart rate by pacing the heart (pacemaker) or terminating abnormally fast heart rhythms (defibrillators)
  • Categories
    • Chamber paced
    • Chamber sensed
    • Response to sensing
    • Programmability, rate modulation
    • Anti-tachycardia functions
24
Q

Pacemaker vs. Defibrilaltor (ICD) Therapy

  • Pacemaker
  • Class I indications for pacemaker implantation
  • Class I indications for defibrillator (ICD) therapy
A
  • Pacemaker
    • Pulse generator + lead wire that conducts energy from the pacemaker to the appropriate place in the heart
  • Class I indications for pacemaker implantation
    • Symptomatic bradycardia
    • Asystole > 3 seconds
    • Asymptomatic complete or high grade AV block w/ an escape rate < 40 bpm
  • Class I indications for defibrillator (ICD) therapy
    • Sudden cardiac deat not due to a transient or reversible cause
    • Sustained, spontaneous VT
    • Severe LV dysfunction that persists despite appropriate therapy
25
Q

Biventricular Pacing / Cardiac Resynchronization Therapy

  • Requirements for patients to receive this therapy
  • Theory behind therapy
A
  • Requirements for patients to receive this therapy
    • History of Class III or IV CHF despite optimal medical therapy
    • History of LBBB
    • EF < 36%
    • QRS > 120ms
  • Theory behind therapy
    • LBBB –> delayed conduction to the LV –> RV & LV beat dyssynchronously
    • Regular RV pacing doesn’t hepl b/c the impulse still takes a long time to travel to the LV
    • Need to pace both the RV & LV
    • Since placing a pacing lead in the LV causes a risk of embolic stroke, the left sided lead is placed in the coronary sinus to pace the LV free wall

Cardiology (40 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions